Empowered by Insilico Medicine’s Pharma.AI platform, ISM8969 demonstrated favorable PD/PK profiles, as well as dose-dependent efficacy in motor functions in animal models. (IMAGE)

InSilico Medicine

Empowered by Insilico Medicine’s Pharma.AI platform, ISM8969 demonstrated favorable PD/PK profiles, as well as dose-dependent efficacy in motor functions in animal models.

Caption

ISM8969 dose dependently improved behavioral performance in open field, rotarod and grip strength tests in MPTP induced Parkinson disease (PD) model

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.